News

ReAlta Life Sciences Invigorates Executive Team with Appointments of David Marek as Chief Executive Officer and Paolo Martini, Ph.D., as Chief Research and Development Officer

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced two distinguished biopharmaceutical veterans to lead the Company: David Marek appointed as Chief Executive Officer and Paolo Martini, Ph.D., appointed as Chief Research and Development Officer.

“As ReAlta evolves into a late-stage development company with multiple clinical programs spanning three distinct therapeutic areas with significant unmet need, I am confident that David and Paolo are the ideal leaders for these two pivotal roles,” said Edward A. Heidt, Jr., Chairperson of ReAlta’s Board of Directors. “David has a strong track record of success driving business transformation including leading an organization with one of the most successful buyouts in recent years, while Paolo’s deep expertise in leading-edge drug discovery and development across an array of therapeutic areas, including rare diseases, will position ReAlta well as we look ahead to delivering potentially life-saving medications for patients with rare and acute inflammatory diseases.”

“It’s rare to find a company so well positioned with a novel scientific approach to take on one of the great challenges in human health – inflammation. Although a key aspect of the body’s immune defenses, inflammation also has significant involvement in the disease process of many conditions and diseases that account for more than half of all deaths globally,” said Mr. Marek. “I am excited to bring my energy and experience to serve as the CEO of ReAlta and am proud to work alongside team members who work tirelessly to break new ground in advancing our mission on behalf of patients.”

“The design of ReAlta’s investigational medicines are inspired by nature – specifically a human enteric virus which has adapted over one billion years of evolution to mitigate inflammation through a dual targeting mechanism that modulates both complement and innate inflammatory pathways. By inhibiting activation of the complement cascade and the neutrophil-driven mechanisms of inflammation and host tissue destruction, ReAlta’s EPICC peptide platform has the potential to provide new hope for patients with rare and acute inflammatory diseases,” said Dr. Martini. “I look forward to advancing our pipeline and to unlocking new opportunities alongside the ReAlta team.”

 

Learn more here.

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …